Markets

Funds are buying these 6 pharmaceutical stocks under $15

By Ben Levine for Kapitall.

It's been a big month for the global pharmaceutical industry. As of Monday, pharmaceutical giant GlaxoSmithKline ( GSK ) has been accused of bribery in Syria as a means to increase sales. Antibiotic-resistant bacteria have been outrunning (and are continuing to outrun) sluggish developments in antibiotic research. A company in Canada called Cannabis Technologies has notably started testing cannabinoids (found in cannabis) for use in treating conditions like MS, glaucoma, epilepsy and cancer.

Clearly, however, the biggest issue facing the global medical industry at large is the ongoing Ebola outbreak in West Africa, the worst the world has ever seen . And it's easily one of the scariest diseases of our time. The World Health Organization just approved the use of experimental drugs in the ongoing effort to stymie the spread of the disease, which has already claimed over a thousand lives.

With all the news and, of course, the never ending pursuit of new pharmaceuticals, funds have been buying up pharmaceutical stocks. To find outperforming pharmaceutical stocks, we took a look at the entirety of publicly traded pharmaceutical stocks with a market cap above $100 million , screened them to see which ones are being bought up by hedge funds and other investment funds, and whittled those down to see which fell between 5 and 15 dollars per share .

Do you think funds' interest in these pharmaceutical stocks could indicate future profits? Take a look at the tools below to begin your analysis, and let us know what you think in the comments.

Click on the interactive chart to view data over time.

1. Alimera Sciences, Inc. ( ALIM , Earnings , Analysts , Financials ): Engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. Market cap at $219.56M, most recent closing price at $6.95.

Net institutional purchases in the current quarter at 2.8M shares, which represents about 18.94% of the company's float of 14.78M shares.

2. Cardiome Pharma Corp. ( CRME , Earnings , Analysts , Financials ): Engages in developing proprietary drugs to treat or prevent cardiovascular and other diseases. Market cap at $105.5M, most recent closing price at $8.46.

Net institutional purchases in the current quarter at 3.7M shares, which represents about 29.11% of the company's float of 12.71M shares.

3. DepoMed Inc. ( DEPO , Earnings , Analysts , Financials ): Develops and commercializes pharmaceutical products based on its proprietary oral drug delivery technologies in the United States. Market cap at $732.4M, most recent closing price at $12.89.

Net institutional purchases in the current quarter at 2.4M shares, which represents about 5.14% of the company's float of 46.69M shares.

4. Horizon Pharma, Inc. ( HZNP , Earnings , Analysts , Financials ): Develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. Market cap at $785.45M, most recent closing price at $12.15.

Net institutional purchases in the current quarter at 10.1M shares, which represents about 23.14% of the company's float of 43.65M shares.

5. Orexigen Therapeutics, Inc. ( OREX , Earnings , Analysts , Financials ): Focuses on the development of pharmaceutical product candidates for the treatment of obesity. Market cap at $706.96M, most recent closing price at $7.16.

Net institutional purchases in the current quarter at 6.3M shares, which represents about 6.06% of the company's float of 104.04M shares.

6. POZEN Inc. ( POZN , Earnings , Analysts , Financials ): Develops products for the treatment of acute and chronic pain, and other pain-related conditions in the United States. Market cap at $249.91M, most recent closing price at $8.20.

Net institutional purchases in the current quarter at 1.8M shares, which represents about 7.51% of the company's float of 23.98M shares.

(List compiled by Ben Levine. Analyst ratings sourced from Zacks Investment Research. All other data sourced from Finviz.)

Kapitall Wire is a division of New Kapitall Holdings, LLC. Kapitall Generation, LLC is a wholly owned subsidiary of New Kapitall Holdings, LLC. Kapitall Wire offers free investing ideas, intended for educational information purposes only. It should not be construed as an offer to buy or sell securities, or any other product or service provided by New Kapitall Holdings, LLC, and its affiliate companies.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Stocks